Q-omics provides the consensus-scored RTN2 profile across patient tissues and cancer cell-line models. RTN2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RTN2 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, RTN2 protein abundance shows 30,442 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight UVM, THCA, and HNSC as cancer lineages where RTN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RTN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RTN2 survival associations across molecular data types. RTN2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RTN2 RNA expression–survival associations across cancer types. High RTN2 expression shows unfavorable associations in MESO, COAD, LAML and ACC, but favorable associations in UVM and LGG. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for RTN2 RNA expression.
This table summarizes RTN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RTN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RTN2 shows lower tumor expression in KICH and higher tumor expression in THCA, KIRC, LIHC, COAD and CHOL. The THCA box plot shows higher RTN2 RNA expression in tumor versus normal tissue (log2 FC = +1.307, t-test p < 0.001).
This table shows molecular features associated with RTN2 in patient tissues and cancer cell lines. In patient samples, RTN2 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, RTN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
